Business ❯ Healthcare Industry

Pharmaceutical Companies

Drug Development Novo Nordisk Drug Pricing Drug Pricing Agreements Drug Supply Chain Pricing Strategies Drug Pricing Strategies Drug Manufacturers Eli Lilly Market Trends Discount Programs Financial Compliance Partnerships Acquisitions Supply Chain CVS Health Daiichi Sankyo Healthcare Fraudulent Practices Oncology Services YourChoice Therapeutics Market Regulation Advertising Practices Biosimilars Market Pfizer Consumer Health Products AstraZeneca Discounted Medications IVF Drug Manufacturing Kenvue Clinical Research EMD Serono Novo Nordisk A/S Direct-to-Consumer Sales Discount Strategies Coherus Oncology Direct-to-Employer Models 340B Program Contractual Relationships Drug Discounts Market Competition Market Performance Vaccine Manufacturers Discount Services Johnson & Johnson Investment Strategies Legal Challenges Liquidia Corp Public Health Contracts Sanofi Regulatory Affairs Gene Therapy Developers Profit Margins Vaccine Development Financial Holdings

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

The weekly shot could improve adherence by replacing daily injections with one dose.

Analyses Find Limited Savings as TrumpRx Reaches 54 Drugs

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

TrumpRx Debuts With 43 Discounted Brand Drugs as Analyses Flag Cheaper Generics and Limits

TrumpRx Launches, Offering Discounted Brand‑Name Drugs Through U.S. Portal

Dr. Oz's CNN Appearance Criticized After 'Gazelle' Remark, On‑Air High‑Five

Regeneron Beats Q4 and Charts 2026 Catalysts With FDA Decisions and Phase III Push

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

White House Unveils 'Great Healthcare Plan' With Sparse Details, Big Budget Questions

Trump Cites 'Very Fat' Friend's Ozempic Story to Decry Price Gap

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

CVS to Pay $37.8 Million to Settle DOJ Insulin Billing Case

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens

Senators Edge Toward 340B Overhaul as CBO Warns on Costs and HRSA Plans 2026 Rebate Pilot

FDA Drug Approvals Slowed in Q3 as Missed Deadlines and CRLs Rose

FDA Sends Mass Warnings, Seeks to End 1997 Drug Ad Rule After White House Directive